AN2 Therapeutics, Inc. (ANTX)
2025-06-30 | ||||
|---|---|---|---|---|
| Unrealized loss on investments | -23 | |||
| Research and development | 3,200 | |||
| General and administrative | 4,016 | |||
| Total operating expenses | 7,216 | |||
| Loss from operations | -7,216 | |||
| Interest income | 754 | |||
| Net loss attributable to common stockholders | -6,462 | |||
| Comprehensive loss | -6,485 | |||
| Earnings per share, basic, total | -0.21 | |||
| Earnings per share, diluted, total | -0.21 | |||
| Weighted average number of shares outstanding, basic, total | 30,172,328 | |||
| Weighted average number of shares outstanding, diluted, total | 30,172,328 | |||